Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narazaciclib - Traws Pharma

Next Previous
Drug Profile

Narazaciclib - Traws Pharma

Alternative Names: HX-301; ON-123300

Latest Information Update: 23 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Temple University
  • Developer HanX Biopharmaceuticals; Traws Pharma
  • Class 2 ring heterocyclic compounds; Aniline compounds; Antineoplastics; Cyclopentanes; Nitriles; Piperidines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Macrophage colony-stimulating factor receptor antagonists; NUAK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Cancer
  • Phase I/II Endometrial cancer; Glioma
  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia; Breast cancer; Mantle-cell lymphoma; Ovarian cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 25 Apr 2025 Pharmacokinetics and pharmacodynamics data from the preclinical studies in Glioblastoma multiforme (GBM) presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 08 Jan 2025 Phase-I/II clinical trials in Glioma (Combination therapy, Recurrent, Second-line therapy or greater) in China (PO) (NCT06703255)
  • 08 Jan 2025 Phase-I/II clinical trials in Glioma (Monotherapy, Recurrent, Second-line therapy or greater) in China (PO) (NCT06703255)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top